Elisabetta Maida

Telemedicine application to headache: a critical review

L. Leocani, G. Tedeschi, R. Iodice, 2022, Neurological Sciences.

Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.

S. Bonavita, L. Lavorgna, G. Miele, 2022, Multiple sclerosis and related disorders.

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

D. Centonze, G. Marfia, C. Pozzilli, 2022, Neurology and Therapy.

Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.

G. Marfia, P. Cavalla, S. Bonavita, 2022, Multiple sclerosis and related disorders.

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series

S. Bonavita, L. Lavorgna, G. Miele, 2022, Journal of clinical medicine.

Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis

S. Bonavita, L. Lavorgna, C. Coppola, 2023, Multiple sclerosis.

Multiple Sclerosis: Diagnosis, Management, and Future Opportunities

L. Lavorgna, Elisabetta Maida, 2023, Journal of clinical medicine.

Viral pericarditis following ocrelizumab in a multiple sclerosis patient

S. Bonavita, G. Miele, G. Abbadessa, 2023, Neurological Sciences.